• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.

作者信息

Stähli Barbara E, Tardif Jean-Claude, Carrier Michel, Gallo Richard, Emery Robert W, Robb Stephen, Cournoyer Daniel, Blondeau Lucie, Johnson Dominique, Mann Jessica, Lespérance Jacques, Guertin Marie-Claude, L'Allier Philippe L

出版信息

J Am Coll Cardiol. 2016 Jan 26;67(3):344-6. doi: 10.1016/j.jacc.2015.10.071.

DOI:10.1016/j.jacc.2015.10.071
PMID:26796402
Abstract
摘要

相似文献

1
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.P-选择素拮抗剂因卡单抗对接受冠状动脉旁路移植术患者的影响：SELECT-CABG试验
J Am Coll Cardiol. 2016 Jan 26;67(3):344-6. doi: 10.1016/j.jacc.2015.10.071.
2
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.依替巴肽拮抗剂依替巴珠单抗对非 ST 段抬高型心肌梗死经皮冠状动脉介入治疗后心肌损伤的影响：SELECT-ACS 试验结果。
J Am Coll Cardiol. 2013 May 21;61(20):2048-55. doi: 10.1016/j.jacc.2013.03.003. Epub 2013 Mar 10.
3
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.人源化抗P-选择素单克隆抗体依库珠单抗的首次人体研究。
J Cardiovasc Pharmacol. 2015 Jun;65(6):611-9. doi: 10.1097/FJC.0000000000000233.
4
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).替卡格雷在接受冠状动脉旁路移植术的急性冠状动脉综合征患者中的应用：TRACER 试验（凝血酶受体拮抗剂在急性冠状动脉综合征临床事件减少中的应用）的亚组分析。
J Am Coll Cardiol. 2014 Mar 25;63(11):1048-57. doi: 10.1016/j.jacc.2013.10.048. Epub 2013 Nov 21.
5
Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers.在健康吸烟者中，因卡单抗与肝素之间不存在药效学相互作用。
J Cardiovasc Pharmacol. 2015 Apr;65(4):386-92. doi: 10.1097/FJC.0000000000000211.
6
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.5'-磷酸吡哆醛（MC-1）在接受冠状动脉旁路移植手术的高危患者中的疗效和安全性：MEND-CABG II随机临床试验
JAMA. 2008 Apr 16;299(15):1777-87. doi: 10.1001/jama.299.15.joc80027. Epub 2008 Apr 1.
7
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.替格瑞洛与氯吡格雷用于行冠状动脉旁路移植术的急性冠状动脉综合征患者：来自 PLATO（血小板抑制和患者结局）试验的结果。
J Am Coll Cardiol. 2011 Feb 8;57(6):672-84. doi: 10.1016/j.jacc.2010.10.029. Epub 2010 Dec 30.
8
Characteristics, management and outcomes of patients with acute coronary syndrome and prior coronary artery bypass surgery: findings from the second Gulf Registry of Acute Coronary Events.急性冠状动脉综合征合并既往冠状动脉搭桥手术患者的特征、管理及预后：第二届海湾急性冠状动脉事件注册研究结果
Interact Cardiovasc Thorac Surg. 2011 Dec;13(6):611-8. doi: 10.1510/icvts.2011.274571. Epub 2011 Sep 13.
9
Successful Revascularization of an LCx CTO Lesion by Retrograde Approach From an Acute Thrombotic SVG Without Protection Device in an ACS Patient.一名急性冠状动脉综合征（ACS）患者在未使用保护装置的情况下，通过来自急性血栓形成的大隐静脉移植物的逆行途径成功实现左回旋支慢性完全闭塞（LCx CTO）病变的血管重建。
Int Heart J. 2016 May 25;57(3):372-5. doi: 10.1536/ihj.15-328. Epub 2016 May 9.
10
Effect of Sustained Use of Aspirin until the Time of Surgery on Outcomes following Coronary Artery Bypass Grafting: A Randomized Clinical Trial.冠状动脉搭桥术后持续使用阿司匹林至手术时对预后的影响：一项随机临床试验
Thorac Cardiovasc Surg. 2018 Sep;66(6):442-451. doi: 10.1055/s-0037-1608686. Epub 2017 Nov 24.

引用本文的文献

1
Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation.靶向P-选择素/PSGL-1通路：发现用于血栓性炎症疾病的疾病修饰疗法。
Blood Vessel Thromb Hemost. 2024 Jun 18;1(3):100015. doi: 10.1016/j.bvth.2024.100015. eCollection 2024 Sep.
2
Dendritic cells immunotargeted therapy for atherosclerosis.树突状细胞免疫靶向治疗动脉粥样硬化
Acta Pharm Sin B. 2025 Feb;15(2):792-808. doi: 10.1016/j.apsb.2024.12.029. Epub 2024 Dec 31.
3
Mechanisms Underlying Vascular Inflammaging: Current Insights and Potential Treatment Approaches.
血管炎症衰老的潜在机制：当前见解与潜在治疗方法
Aging Dis. 2024 Oct 18;16(4):1889-1917. doi: 10.14336/AD.2024.0922.
4
Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.蛋白质和脂类唾液酸化在人类疾病中的作用机制和治疗意义。
Int J Mol Sci. 2024 Nov 7;25(22):11962. doi: 10.3390/ijms252211962.
5
Reduced Monocyte and Neutrophil Infiltration and Activation by P-Selectin/CD62P Inhibition Enhances Thrombus Resolution in Mice.P-选择素/CD62P 抑制减少单核细胞和中性粒细胞浸润与激活，增强小鼠血栓溶解。
Arterioscler Thromb Vasc Biol. 2024 Apr;44(4):954-968. doi: 10.1161/ATVBAHA.123.320016. Epub 2024 Feb 22.
6
Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention.血小板与动脉粥样硬化进程：血小板活化及反应性新标志物概述及其在一级和二级预防中的意义
J Clin Med. 2023 Sep 20;12(18):6074. doi: 10.3390/jcm12186074.
7
Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation.无载体颗粒将中性粒细胞-血小板聚集体转移，以减少血栓炎症。
Nat Commun. 2023 Apr 28;14(1):2462. doi: 10.1038/s41467-023-37990-z.
8
Modern Concepts in Cardiovascular Disease: Inflamm-Aging.心血管疾病的现代概念：炎症与衰老。
Front Cell Dev Biol. 2022 May 18;10:882211. doi: 10.3389/fcell.2022.882211. eCollection 2022.
9
Neutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease.中性粒细胞与血小板的相互作用作为心血管疾病的新型治疗靶点
Front Cardiovasc Med. 2022 Jan 31;8:824112. doi: 10.3389/fcvm.2021.824112. eCollection 2021.
10
The Role of C-reactive Protein in Patient Risk Stratification and Treatment.C反应蛋白在患者风险分层及治疗中的作用
Eur Cardiol. 2021 Jul 7;16:e28. doi: 10.15420/ecr.2020.49. eCollection 2021 Feb.